熱門資訊> 正文
Surmodics超出了顶线和底线估计;暂停年度指导
2024-07-31 20:53
- Surmodics press release (NASDAQ:SRDX): Q3 Non-GAAP EPS of -$0.27 beats by $0.06.
- Revenue of $30.3M (-42.3% Y/Y) beats by $0.29M.
- Adjusted EBITDA was $1.6M, compared to Adjusted EBITDA of $24.6M in the third quarter of fiscal 2023.
- As of June 30, 2024, Surmodics reported $38.2M in cash and investments, $5M in outstanding borrowings on its revolving credit facility, and $25M in outstanding borrowings on its term loan facility.
- The company is suspending its previously issued financial guidance for fiscal 2024 in light of the pending acquisition by GTCR.
More on Surmodics
- Surmodics jumps 18% on acquisition by GTCR
- Seeking Alpha’s Quant Rating on Surmodics
- Historical earnings data for Surmodics
- Financial information for Surmodics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
